Cargando…
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
BACKGROUND: Adequate response to the SARS-CoV-2 vaccine represents an important treatment goal in caring for patients with multiple sclerosis (MS) during the ongoing COVID-19 pandemic. Previous data so far have demonstrated lower spike-specific IgG responses following two SARS-CoV-2 vaccinations in...
Autores principales: | Sabatino, Joseph J., Mittl, Kristen, Rowles, William, Zamecnik, Colin R., Loudermilk, Rita P., Gerungan, Chloe, Spencer, Collin M., Sagan, Sharon A., Alexander, Jessa, Mcpolin, Kira, Chen, PeiXi, Deshpande, Chinmay, Wyse, Kerri, Maiese, Eric M., Wilson, Michael R., Zamvil, Scott S., Bove, Riley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794398/ https://www.ncbi.nlm.nih.gov/pubmed/36608538 http://dx.doi.org/10.1016/j.msard.2022.104484 |
Ejemplares similares
-
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
por: Sabatino, Joseph J., et al.
Publicado: (2021) -
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
por: Sabatino, Joseph J., et al.
Publicado: (2022) -
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021) -
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
por: Bajwa, Hamza Mahmood, et al.
Publicado: (2022) -
Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data
por: Rowles, William M., et al.
Publicado: (2022)